In8bio, Inc. (INAB) Stock Price & Analysis
In8bio, Inc. (INAB) rose 0.69% to USD 1.45 as of June 10, 2026 at 02:17 UTC, according to Nexqual real-time market data.
INAB last closed at USD 1.44; the session ranged USD 1.4–1.49 on volume of 34,244 shares. Market capitalization is $13.91M, with a 52-week range of USD 1.17–2.9 (NCM). Source: Nexqual, June 10, 2026 at 02:17 UTC.
Key Statistics (as of June 10, 2026 at 02:17 UTC)
| Price | USD 1.45 |
|---|---|
| Change | ▲ 0.69% (up) |
| Previous Close | USD 1.44 |
| Open | USD 1.4 |
| Day Range | USD 1.4 – 1.49 |
| 52-Week Range | USD 1.17 – 2.9 |
| Volume | 34,244 shares |
| Market Cap | $13.91M |
| Exchange | NCM |
Technical Analysis (INAB)
Nexqual's technical model rates INAB "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:17 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.48 (neutral) |
| vs SMA50 | Below (USD 1.53) |
| MACD | -0.02 (negative) |
Analyst Ratings (INAB)
Wall Street analysts rate INAB "Strong Buy" based on 4 analysts, with a mean price target of USD 6.25 (range USD 4–10), per Nexqual as of June 10, 2026 at 02:17 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 6.25 |
| High Target | USD 10 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (INAB)
| EPS Estimate | USD -0.37 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.26 vs est -0.69 ▲ beat |
| 2025-12-31 | USD -0.45 vs est -0.48 ▲ beat |
| 2025-09-30 | USD -0.85 vs est -1.25 ▲ beat |
| 2025-06-30 | USD -1.24 vs est -1.8 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:17 UTC.
Financials & Fundamentals (INAB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -103.55% |
| Debt / Equity | 10.33 |
| Current Ratio | 10.5 |
| Total Cash | $21.94M |
| Total Debt | $2.35M |
| Free Cash Flow | $-7.13M |
Source: Nexqual, June 10, 2026 at 02:17 UTC.
Financial Health Score (INAB)
Nexqual rates In8bio, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:17 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $22M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$15M |
| Efficiency | Critical — ROE -104%, ROA -52.7% |
Ownership (INAB)
| Insider Ownership | +13.40% |
|---|---|
| Institutional Ownership | +38.12% |
| Shares Outstanding | 9.59M |
| Float | 7.03M |
| Short % of Float | +1.22% |
Source: Nexqual, June 10, 2026 at 02:17 UTC.
Leadership (INAB)
In8bio, Inc. is led by Tai-Wei Ho (age 48), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 02:17 UTC.
| Co-Founder, CEO & Director | Tai-Wei Ho (age 48) |
|---|---|
| President & COO | Kate Rochlin (age 43) |
| CFO & Secretary | Patrick McCall (age 41) |
| Executive VP, Co-Founder & Chief Scientific Officer | Lawrence S. Lamb (age 70) |
Major Backers & Investors (INAB)
Notable institutional backers of In8bio, Inc. include Alyeska Investment Group, L.p., Franklin Resources, Inc., 683 Capital Management LLC, according to Nexqual as of June 10, 2026 at 02:17 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Alyeska Investment Group, L.p. | 9.59% |
| Franklin Resources, Inc. | 9.29% |
| 683 Capital Management LLC | 7.36% |
| Stonepine Capital Management, LLC | 6.74% |
| Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | 3.37% |
| Bios Capital Management, LP | 1.7% |
| Fidelity | 0.76% |
| CAPTRUST Financial Advisors | 0.34% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.24% |
| Geode Capital | 0.88% |
Source: Nexqual, June 10, 2026 at 02:17 UTC.
From In8bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.
- Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
- The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager.
- In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.94 | ▼ 1.02% |
| PXMD | PaxMedica, Inc. | USD 0 | ▲ 0% |
| SPRC | SciSparc Ltd. | USD 9.31 | ▼ 18.62% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.2 | ▲ 1.69% |
| KPRX | Kiora Pharmaceuticals, Inc. | USD 2.59 | ▲ 3.6% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:17 UTC. This page is informational and not investment advice.